340 related articles for article (PubMed ID: 28439725)
21. [Mucositis after allogeneic stem cell transplantation: Risk factors, clinical consequences and prophylaxis].
Bourdelin M; Daguindau E; Larosa F; Legrand F; Nerich V; Deconinck E; Limat S
Pathol Biol (Paris); 2015 Apr; 63(2):106-10. PubMed ID: 25555496
[TBL] [Abstract][Full Text] [Related]
22. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
[TBL] [Abstract][Full Text] [Related]
23. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
24. Pretransplantation Inflammatory and Nutritional Status in Elderly Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Value of C-Reactive Protein-to-Albumin Ratio.
Miyazaki T; Tachibana T; Suzuki T; Izumi A; Fujimaki K; Sato S; Tamai Y; Michishita Y; Suzuki T; Ishii R; Hirasawa A; Hashimoto C; Kabasawa N; Inoue Y; Ishiyama T; Yamamoto K; Kanamori H; Tanaka M; Nakajima H
Transplant Cell Ther; 2024 Apr; 30(4):400.e1-400.e9. PubMed ID: 38253183
[TBL] [Abstract][Full Text] [Related]
25. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
26. Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.
Beckerson J; Szydlo RM; Hickson M; Mactier CE; Innes AJ; Gabriel IH; Palanicawandar R; Kanfer EJ; Macdonald DH; Milojkovic D; Rahemtulla A; Chaidos A; Karadimitris A; Olavarria E; Apperley JF; Pavlu J
Clin Nutr; 2019 Apr; 38(2):738-744. PubMed ID: 29650256
[TBL] [Abstract][Full Text] [Related]
27. Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival.
Kordelas L; Buttkereit U; Heinemann FM; Horn PA; Giebel B; Beelen DW; Reinhardt HC; Rebmann V
Front Immunol; 2021; 12():694843. PubMed ID: 34630383
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of sarcopenia and relevance of nutritional intake in patients before and after allogeneic hematopoietic stem cell transplantation.
Tanaka S; Imataki O; Kitaoka A; Fujioka S; Hanabusa E; Ohbayashi Y; Uemura M; Arima N; Yamamoto T
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1083-1092. PubMed ID: 28224299
[TBL] [Abstract][Full Text] [Related]
29. Nutritional risk factors predict severe acute graft-versus-host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation.
Kerby EH; Li Y; Getz KD; Smith EC; Smith LT; Bunin NJ; Seif AE
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29080380
[TBL] [Abstract][Full Text] [Related]
30. Evolution of nutritional status in patients with autologous and allogeneic hematopoietic stem cell transplant.
Barritta de Defranchi RL; Bordalejo A; Cañueto I; Villar A; Navarro E
Support Care Cancer; 2015 May; 23(5):1341-7. PubMed ID: 25347950
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
Liao YP; Jiang JL; Zou WY; Xu DR; Li J
World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
[TBL] [Abstract][Full Text] [Related]
32. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
33. CTLA-4 polymorphisms: influence on transplant-related mortality and survival in children undergoing allogeneic hematopoietic stem cell transplantation.
Hammrich J; Wittig S; Ernst T; Gruhn B
J Cancer Res Clin Oncol; 2018 Mar; 144(3):587-592. PubMed ID: 29335768
[TBL] [Abstract][Full Text] [Related]
34. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
Jaskula E; Lange A; Kyrcz-Krzemien S; Markiewicz M; Dzierzak-Mietla M; Jedrzejczak WW; Czajka P; Mordak-Domagala M; Lange J; Gronkowska A; Nowak J; Warzocha K; Hellmann A; Kowalczyk J; Drabko K; Gozdzik J; Mizia S;
Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
[TBL] [Abstract][Full Text] [Related]
35. Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.
Shibasaki Y; Suwabe T; Katagiri T; Tanaka T; Ushiki T; Fuse K; Sato N; Yano T; Kuroha T; Hashimoto S; Narita M; Furukawa T; Sone H; Masuko M
Int J Hematol; 2018 Sep; 108(3):282-289. PubMed ID: 29744806
[TBL] [Abstract][Full Text] [Related]
36. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
37. Biochemical indices for the assessment of nutritional status during hematopoietic stem cell transplantation: are they worth using? A single center experience.
Rzepecki P; Barzal J; Sarosiek T; Szczylik C
Bone Marrow Transplant; 2007 Sep; 40(6):567-72. PubMed ID: 17637693
[TBL] [Abstract][Full Text] [Related]
38. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
[TBL] [Abstract][Full Text] [Related]
39. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
40. Conjunctival Acute Graft-versus-Host Disease in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study.
Liu YC; Gau JP; Lin PY; Liu CJ; Liu CJ; Liu JH; Fan NW
PLoS One; 2016; 11(11):e0167129. PubMed ID: 27902756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
